30 May 2018 – Scientific Advisory Board

Destiny Pharma has today announced the formation of a new Scientific Advisory Board (SAB) to provide expert, independent analysis of the Company’s research and clinical development plans and to help in developing clinical strategies for its unique XF Platform.

Further details of the SAB can be found here.